Recombinant therapeutic protein drug conjugate (Pre-made Tagraxofusp biosimilar, Protein drug conjugate) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It was approved for use in the United States in 218, and after a second review, in the EU in January 221. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Tagraxofusp is an engineered molecule composed of Diptheria toxin covalently attached to a portion of the interleukin-3 cytokine. The drug binds to the ¦Â-chain of the interleukin-3 receptor (CD123), which mediates endocytosis.51 The Diptheria toxin is subsequently released and induces cytotoxicity through protein inhibition.